Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Hemab Therapeutics Holdings, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $27.13
+13% in 7d after detection
Post-detection moves
1h
—
1d
-1.3%
3d
+1.6%
7d
+13%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS